An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
Completed
Mitsubishi Tanabe Pharma Corporation
Phase 2
2008-04-01
This study was an extension study of NCT00537082. This study was designed to evaluate the
efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720)
to relapsing multiple sclerosis.
An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple Sclerosis
Completed
Novartis
Phase 2
2008-04-01
This study was an extension study of NCT00537082. This study was designed to evaluate the
efficacy and safety of long-term administration of 0.5 mg or 1.25 mg of fingolimod (FTY720)
to relapsing multiple sclerosis.
The purpose of the Multi-National Gilenya Pregnancy Exposure Registry in Multiple Sclerosis
(MS) is to continuously monitor, evaluate, and assess for major and minor teratogenic effects
in the offspring of women exposed to Gilenya before (up to 8 weeks before last menstrual
period) and during pregnancy in routine clinical practice. The overall aim is to collect and
evaluate data on maternal, fetal, and infant outcomes and compare it with reference
populations.
Approximately 50% of people diagnosed with Multiple Sclerosis (MS) will develop problems with
cognition. Currently, there are no FDA-approved treatments targeting cognitive function in
Multiple Sclerosis. This trial will ascertain whether treatment with an estrogen pill, used
in combination with standard MS anti-inflammatory drugs, can improve cognitive testing as
compared to treatment with a placebo pill in combination with standard anti-inflammatory
drugs in women with MS.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
